Evidence map›Paper›PMID 36259015›Full record

ReviewCureus2022

The Use of Psychedelics in the Treatment of Medical Conditions: An Analysis of Currently Registered Psychedelics Studies in the American Drug Trial Registry.

Joshua S Kurtz, Neal A Patel, Julian L Gendreau, Chenyi Yang, Nolan Brown, Nick Bui, Bryce Picton, Mark Harris, Matthew Hatter, Ryan Beyer and 5 more

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Joshua S KurtzNeurological Surgery, University of California Irvine, Irvine, USA.
Neal A PatelNeurological Surgery, Mercer University School of Medicine, Savannah, USA.
Julian L GendreauBiomedical Engineering, Johns Hopkins University, Baltimore, USA.
Chenyi YangNeurological Surgery, University of California Irvine, Irvine, USA.
Nolan BrownNeurological Surgery, University of California Irvine, Irvine, USA.
Nick BuiNeurological Surgery, Loma Linda School of Medicine, Loma Linda, USA.
Bryce PictonNeurological Surgery, University of California Irvine (UCI) School of Medicine, Irvine, USA.
Mark HarrisNeurological Surgery, UCI, School of Medicine,, Irvine, USA.
Matthew HatterNeurological Surgery, University of California Irvine (UCI) School of Medicine, Irvine, USA.
Ryan BeyerNeurological Surgery, University of California Irvine (UCI) School of Medicine, Irvine, USA.
Ronald SahyouniNeurological Surgery, University of California San Diego, San Diego, USA.
Luis Daniel Diaz-AguilarNeurological Surgery, University of California San Diego, San Diego, USA.
Joel CastellanosAnesthesiology and Reanimation, University of California San Diego, San Diego, USA.
Nathaniel SchusterCenter for Pain Medicine, University of California San Diego, San Diego, USA.
Mickey E AbrahamNeurological Surgery, University of California San Diego, San Diego, USA.
University of California, Irvine · USUniversity of California, San Diego · USNeurological Surgery · USJohns Hopkins University · USLoma Linda University · USMercer University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although early therapeutic research on psychedelics dates back to the 1940s, this field of investigation was met with many cultural and legal challenges in the 1970s. Over the past two decades, clinical trials using psychedelics have resumed. Therefore, the goal of this study was to (1) better characterize the recent uptrend in psychedelics in clinical trials and (2) identify areas where potentially new clinical trials could be initiated to help in the treatment of widely prevalent medical disorders. A systematic search was conducted on the clinicaltrials.gov database for all registered clinical trials examining the use of psychedelic drugs and was both qualitatively and quantitatively assessed. Analysis of recent studies registered in clinicaltrials.gov was performed using Pearson's correlation coefficient testing. Statistical analysis and visualization were performed using R software. In totality, 105 clinical trials met this study's inclusion criteria. The recent uptrend in registered clinical trials studying psychedelics (p = 0.002) was similar to the uptrend in total registered clinical trials in the registry (p < 0.001). All trials took place from 2007 to 2020, with 77.1% of studies starting in 2017 or later. A majority of clinical trials were in phase 1 (53.3%) or phase 2 (25.7%). Common disorders treated include substance addiction, post-traumatic stress disorder, and major depressive disorder. Potential research gaps include studying psychedelics as a potential option for symptomatic treatment during opioid tapering. There appears to be a recent uptrend in registered clinical trials studying psychedelics, which is similar to the recent increase in overall trials registered. Potentially, more studies could be performed to evaluate the potential of psychedelics for symptomatic treatment during opioid tapering and depression refractory to selective serotonin reuptake inhibitors.

Indexed as

clinical trialsmajor depressive disordermdmapost traumatic stress disorderpsilocybin

Identifiers

PMID36259015
PMCPMC9567237
OpenAlexW4295789857

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.